115 related articles for article (PubMed ID: 1516581)
1. Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1992; 13(4):316-8. PubMed ID: 1516581
[TBL] [Abstract][Full Text] [Related]
2. [Combination chemotherapy with cisplatin and etoposide for cerebellar metastasis from ovarian adenocarcinoma].
Itoyama Y; Seto H; Kochi M; Kuratsu J; Korematsu K; Kitano I; Uemura S; Ushio Y
No Shinkei Geka; 1991 Aug; 19(8):751-4. PubMed ID: 1896120
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus VP16-213 in refractory ovarian carcinoma.
Lele SB; Piver MS; Malfetano J
Am J Clin Oncol; 1987 Feb; 10(1):21-2. PubMed ID: 3825989
[TBL] [Abstract][Full Text] [Related]
4. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.
Baker TR; Piver MS; Hempling RE
Eur J Gynaecol Oncol; 1993; 14(1):18-22. PubMed ID: 8472726
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1995; 16(1):12-7. PubMed ID: 7744111
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide.
Zanaboni F; Scarfone G; Presti M; Maggi R; Borello C; Bolis G
Gynecol Oncol; 1991 Oct; 43(1):24-8. PubMed ID: 1959783
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer.
Creagan ET; Richardson RL; Kovach JS
J Clin Oncol; 1988 Jul; 6(7):1197-201. PubMed ID: 2839633
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin plus VP 16-213 in advanced ovarian carcinoma.
Harnett PR; Bell DR; Hillcoat BL; Woods RL; Levi JA; Rome RM; Campbell JC; Tattersall MH
Gynecol Oncol; 1988 Jun; 30(2):159-62. PubMed ID: 3371739
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
10. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
J Surg Oncol; 1986 May; 32(1):43-5. PubMed ID: 3724190
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
12. "Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".
Piver MS
Cancer Treat Rep; 1986 Dec; 70(12):1466. PubMed ID: 3791262
[No Abstract] [Full Text] [Related]
13. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
Sakaihara M; Sakai K; Hara Y; Kataoka S; Tabata M; Hanatani K; Hareyama H
Gan To Kagaku Ryoho; 2000 Jan; 27(1):127-30. PubMed ID: 10660745
[TBL] [Abstract][Full Text] [Related]
15. New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas.
Chen JT; Hirai Y; Shimizu Y; Hasumi K; Masubuchi K
Gynecol Oncol; 1990 Jul; 38(1):1-5. PubMed ID: 2354814
[TBL] [Abstract][Full Text] [Related]
16. [Pilot phase II trial of high-dose etoposide combined with cisplatin in the treatment of refractory lung cancer].
Fujita J; Morikawa N; Yamaji Y; Kubo A; Takigawa K; Yamagishi Y; Fujita T; Shiotani T; Takahara J; Irino S
Gan To Kagaku Ryoho; 1992 Jun; 19(6):849-54. PubMed ID: 1318697
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
